SG/CALL/EDWARDS LIFESCIENCES/110/0.1/16.01.26 | Real-time Boerse Frankfurt Warrants 08:19:57 17/05/2024 pm IST | ||
| 1.83 EUR | -5.18% |
|
| Current month | +11.56% | ||
| 1 month | -10.23% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about EDWARDS LIFESCIENCES CORPORATION
More news
| Date | Price | Change |
|---|---|---|
| 17/24/17 | 1.83 | -5.18% |
| 16/24/16 | 1.93 | +1.58% |
| 15/24/15 | 1.9 | +9.20% |
| 14/24/14 | 1.74 | +6.10% |
| 13/24/13 | 1.64 | -6.82% |
Real-time Boerse Frankfurt Warrants
Last update May 17, 2024 at 08:19 pm IST
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | EDWARDS LIFESCIENCES CORPORATION |
| Issuer | 
Société Générale
|
| WKN | SW8QPV |
| ISIN | DE000SW8QPV4 |
| Date issued | 08/04/2024 |
| Strike | 110 $ |
| Maturity | 16/01/2026 (609 Days) |
| Parity | 10 : 1 |
| Emission price | 2.26 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 2.26 € |
|---|---|
| Lowest since issue | 1.58 € |
| Spread | 0.01 € |
| Spread % | 0.54% |
Company Profile
Edwards Lifesciences Corporation specializes in designing, manufacturing and marketing medical systems and devices for treating cardiovascular diseases. Net sales break down by family of products as follows:
- heart valves and surgery products (67.9%);
- hemodynamic monitoring systems (15.5%);
- other (16.6%): balloon catheters, artificial implants, etc.
Net sales are distributed geographically as follows: the United States (58.4%), Europe (22.2%), Japan (7.6%) and other (11.8%).
Sector
-
Ratings for Edwards Lifesciences Corporation
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Edwards Lifesciences Corporation
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
90.11
USD
Average target price
95.9
USD
Spread / Average Target
+6.43%
- Stock Market
- Warrants
- Warrant